Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Second Toe Length and Hallux Valgus: Greek vs. Egyptian Foot

NCT06874517 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2025-03-10
Last updated
2025-03-26

Condition(s) studied

Hallux Valgus

Investigational drug(s) / intervention(s)

no intervention

no intervention: no intervention

Study summary

A total of 150 patients aged 60-80 years with existing foot radiographs will be included in the study. Radiographic evaluations will include measurements of the hallux valgus angle, first intermetatarsal angle, and the metatarsal and phalanx lengths of the first and second toes. The ratio of the second toe phalanx length to the first toe phalanx length will be calculated and recorded. The relationship between the hallux valgus angle, toe lengths, and their ratios will be analyzed using statistical methods.

Eligibility

Sex
ALL
Min age
60 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 60-80 years * Presence of foot radiographs suitable for measurement * No history of prior foot surgery Exclusion Criteria: * History of foot trauma or fractures * Previous foot or toe surgery * Presence of congenital foot deformities * Neurological or rheumatologic conditions affecting foot structure * Severe osteoarthritis or other degenerative foot diseases visible on radiographs

Primary outcome measure(s)

  • Hallux Valgus Angle — 0 day
    The angle between the first metatarsal and the proximal phalanx of the first toe, measured on radiographs. Higher values indicate greater hallux valgus severity.

Trial sites (1)

FacilityCityRegionStatus
Beylikdüzü State Hospital Istanbul Beylikdüzü Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06874517 on ClinicalTrials.gov ↗ ← All trials in Turkey